Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of
autologous genetically engineered T cells expressing a single-domain antibody that recognizes
human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated
into the endogenous T cell receptor (TCR) complex.
This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently
determine an overall response rate in patients with advanced mesothelin-expressing cancers.